International multicenter real-world REGistry for patients with metastatic renAL cell carcinoma – Meet-URO 33 study (REGAL study)

Abstract Background Nowadays, different therapeutic options are available for the first-line treatment of metastatic renal cell carcinoma (mRCC). Immuno-combinations are the standard first-line therapy in all mRCC patients regardless of the International Metastatic RCC Database Consortium (IMDC) ris...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Sara Elena Rebuzzi, Giuseppe Fornarini, Alessio Signori, Sebastiano Buti, Giuseppe Procopio, Ugo De Giorgi, Sandro Pignata, Emanuele Naglieri, Marco Maruzzo, Giuseppe Luigi Banna, Pasquale Rescigno, Carlo Messina, Alvise Mattana, Umberto Basso, Davide Bimbatti
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	BMC 2024-06-01
Serie:	BMC Cancer
Ämnen:	Metastatic renal cell carcinoma Immunotherapy Immune checkpoint inhibitor Clinical practice Real-world IMDC score
Länkar:	https://doi.org/10.1186/s12885-024-12319-1
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!